Pfizer’s (PFE) Outperform Rating Reiterated at BMO Capital Markets
Pfizer Inc. (NYSE:PFE)‘s stock had its “outperform” rating restated by research analysts at BMO Capital Markets in a report released on Tuesday. They presently have a $40.00 price objective on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would indicate a potential upside of 22.36% from the stock’s previous close.
PFE has been the subject of several other reports. Vetr raised Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.42 price objective for the company in a report on Monday. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Pfizer in a report on Monday, September 26th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $54.00 price objective on shares of Pfizer in a report on Monday, June 27th. JPMorgan Chase & Co. set a $40.00 price objective on Pfizer and gave the company a “buy” rating in a report on Monday, July 25th. Finally, Barclays PLC reaffirmed an “equal weight” rating and issued a $34.00 price objective on shares of Pfizer in a report on Tuesday, August 2nd. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $38.63.
Shares of Pfizer (NYSE:PFE) traded up 0.58% during trading on Tuesday, hitting $32.69. The stock had a trading volume of 14,823,025 shares. Pfizer has a one year low of $28.25 and a one year high of $37.39. The stock has a 50 day moving average price of $33.95 and a 200-day moving average price of $34.35. The stock has a market capitalization of $198.29 billion, a price-to-earnings ratio of 28.98 and a beta of 0.86.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/pfizers-pfe-outperform-rating-reiterated-at-bmo-capital-markets.html
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period last year, the firm posted $0.56 EPS. On average, equities research analysts predict that Pfizer will post $2.46 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be paid a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 3.67%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 95.24%.
A number of hedge funds and other institutional investors have recently bought and sold shares of PFE. Murphy Pohlad Asset Management LLC increased its position in Pfizer by 12.8% in the first quarter. Murphy Pohlad Asset Management LLC now owns 59,141 shares of the biopharmaceutical company’s stock worth $1,752,000 after buying an additional 6,710 shares during the period. PM CAPITAL Ltd bought a new stake in shares of Pfizer during the first quarter worth approximately $39,264,000. Bridges Investment Management Inc. raised its stake in shares of Pfizer by 1.1% in the first quarter. Bridges Investment Management Inc. now owns 28,220 shares of the biopharmaceutical company’s stock worth $946,000 after buying an additional 313 shares in the last quarter. Lincluden Management Ltd. raised its stake in shares of Pfizer by 6.6% in the first quarter. Lincluden Management Ltd. now owns 160,972 shares of the biopharmaceutical company’s stock worth $4,771,000 after buying an additional 9,925 shares in the last quarter. Finally, ST Germain D J Co. Inc. raised its stake in shares of Pfizer by 3.4% in the first quarter. ST Germain D J Co. Inc. now owns 113,970 shares of the biopharmaceutical company’s stock worth $3,378,000 after buying an additional 3,778 shares in the last quarter. 69.66% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.